Clinical Trial: Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL

U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07778212) titled 'Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL' on July 21.

Brief Summary: To evaluate orelabrutinib in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) as first-line treatment for patients with intermediate- to high-risk diffuse large B-cell lymphoma (DLBCL).

Study Start Date: Aug. 30

Study Type: INTERVENTIONAL

Condition: DLBCL - Diffuse Large B Cell Lymphoma Intermediate-High Risk First-Line

Intervention: DRUG: Orelabrutinib Combined with Pola-R-CHP Regimen

Participants will receive orelabrutinib 150...